Absence of specific cell killing of the BRCA2-deficient human cancer cell line CAPAN1 by poly(ADP-ribose) polymerase inhibition

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Cancer Biology & Therapy

• Publication date

  2005-05-25

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4161/cbt.4.7.1909PMID 16082177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• BRCA2 regulates homologous recombination in response to DNA damage: implications for genome stability and carcinogenesis.

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• Exploiting different ways to die.

  2004cited by this paper
• Alkylating DNA damage stimulates a regulated form of necrotic cell death.

  2004cited by this paper
• Large-Scale Allelotype of Pancreaticobiliary Carcinoma Provides Quantitative Estimates of Genome-Wide Allelic Loss

  2004cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Homologous repair of DNA damage and tumorigenesis:the BRCA connection

  2002cited by this paper
• BRCA2 is required for homology-directed repair of chromosomal breaks.

  2001cited by this paper
• Mutation in Brca2 stimulates error‐prone homology‐directed repair of DNA double‐strand breaks occurring between repeated sequences

  2001cited by this paper
• Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations.

  1999cited by this paper
• BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.

  1999cited by this paper
• The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment.

  1998cited by this paper
• Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).

  1998cited by this paper
• Tumor-suppressive pathways in pancreatic carcinoma.

  1997cited by this paper
• Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.

  1996cited by this paper
• Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo.

  1989cited by this paper

• Advances in Synthetic Lethality in Potential Oncology Therapeutic Approaches.

  2025cites this paper
• Carbamoylation at C-8 position of natural 3-arylcoumarin scaffold for the discovery of novel PARP-1 inhibitors with potent anticancer activity.

  2024cites this paper
• Mitotic MTH1 Inhibitors in Treatment of Cancer.

  2023cites this paper
• Counting the cost of public and philanthropic R&D funding: the case of olaparib

  2022cites this paper
• MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple-negative breast cancer cells

  2021cites this paper
• Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types

  2021cites this paper
• The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity

  2020influential citation
• WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner

  2016cites this paper
• PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells

  2016cites this paper
• Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptormediated apoptosis

  2016cites this paper
• Poly(ADP-ribose) glycohydrolase silencing down-regulates TCTP and Cofilin-1 associated with metastasis in benzo(a)pyrene carcinogenesis.

  2015cites this paper
• The molecular mechanism of PARP1 activationand its downstream roles in ALC1-regulatedtranscription

  2015cites this paper
• A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells

  2014cites this paper
• Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells

  2014cites this paper
• Opportunities for translation: targeting DNA repair pathways in pancreatic cancer.

  2014cites this paper
• PARP and PARP Inhibitor Therapeutics

  2013cites this paper
• Mitoxantrone Targets Human Ubiquitin-Specific Peptidase 11 (USP11) and Is a Potent Inhibitor of Pancreatic Cancer Cell Survival

  2013cites this paper
• Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines

  2013cites this paper
• [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].

  2012cites this paper
• Targeted therapy for brain tumours: role of PARP inhibitors.

  2012cites this paper
• Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

  2012cites this paper
• PARP1 expression in breast cancer and effects of its inhibition in preclinical models

  2012cites this paper
• Targeting PARP-1 in Breast Cancer: Th e Paradigm of a DNA Repair-based Th erapeutic Strategy

  2012cites this paper
• Chapter 4 – The role of PARP in DNA repair and its therapeutic exploitation

  2012cites this paper
• The potential of the PARP-1 inhibitor, AGO14699, in human cancers defective in homologous recombination DNA repair

  2012cites this paper
• Hodnocení variant nejasného významu v genu BRCA 2 Evaluation of Variants of Unknown Significance in the BRCA 2 gene

  2012cites this paper
• Tumour-Specific Synthetic Lethality: Targeting BRCA Dysfunction in Ovarian Cancer

  2011cites this paper
• How to kill tumor cells with inhibitors of poly(ADP‐ribosyl)ation

  2011cites this paper
• The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment.

  2011cites this paper
• Drug therapy for hereditary cancers

  2011cites this paper
• Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.

  2011cites this paper
• DNA repair: exploiting the Fanconi anemia pathway as a potential therapeutic target.

  2011cites this paper
• The role of PARP in DNA repair and its therapeutic exploitation

  2011cites this paper
• Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

  2010cites this paper
• Proteomique fonctionnelle des poly(ADP-Ribose) polymerases

  2010cites this paper
• Genetic inactivation of the Fanconi anemia gene FANCC identified in the hepatocellular carcinoma cell line HuH-7 confers sensitivity towards DNA-interstrand crosslinking agents

  2010cites this paper
• Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes

  2010cites this paper
• Open Access RESEARCH

  2010cites this paper
• Molecular pathways involved in cell death after chemically induced DNA damage.

  2009cites this paper
• PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.

  2009cites this paper
• PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.

  2009cites this paper
• DNA repair deficiency as a therapeutic target in cancer.

  2008cites this paper
• A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair.

  2008cites this paper
• Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin

  2008cites this paper
• Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas.

  2008cites this paper
• Can genetic testing guide treatment in breast cancer?

  2008cites this paper
• Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment

  2008influential citation
• The role of PARP-1 induced AKT activation in cytostatic resistance

  2008cites this paper
• DNA repair proteins as molecular targets for cancer therapeutics.

  2008cites this paper
• Hereditary breast cancer: from molecular pathology to tailored therapies

  2008cites this paper
• Selective Inhibition of BRCA 2-Deficient MammaryTumor Cell Growth byAZD 2281 and Cisplatin

  2008cites this paper
• PolyADP‐ribosylation and cancer

  2007cites this paper
• Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.

  2007cites this paper
• Distinguishing Rational from Irrational Applications of Pharmacogenetic Synergies from the Bench to Clinical Trials

  2007cites this paper
• p53, BRCA1 and breast Cancer chemoresistance.

  2007cites this paper
• Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology

  2007cites this paper
• High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.

  2007cites this paper
• Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models

  2007cites this paper
• Targeting DNA repair proteins: a promising avenue for cancer gene therapy.

  2006cites this paper
• PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

  2006influential citation
• Quantitative correlation between cellular proliferation and nuclear poly (ADP-ribose) polymerase (PARP-1).

  2006cites this paper
• Targeting Fanconi Anemia / BRCA 2 Pathway Defects in Cancer : The Significance of Preclinical

  2006cites this paper
• The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors

  2006cites this paper
• Poly(ADP-ribose) polymerase inhibition and its potential use in malignant melanoma

  2006cites this paper
• Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition.

  2006cites this paper
• Targeted therapy for BRCA2 deficient tumors

  2005cites this paper
• DNA repair inhibition: a selective tumour targeting strategy.

  2005cites this paper
• BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency

  2005cites this paper
• Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy.

  2005cites this paper